Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glutamine shows promise for thalassemia lung complication

NCT ID NCT07210450

Disease control Sponsor: Mazandaran University of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tested whether L-glutamine, a common supplement, can reduce high blood pressure in the lungs of adults with non-transfusion-dependent thalassemia. Eight participants took either glutamine plus standard care or standard care alone for 60 days. The main goal was to see if glutamine could lower lung artery pressure measured by ultrasound. The study is complete, but results are not yet reported.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

8 people

The number who actually took part.

Started

Aug 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years), any sex. * Diagnosis of non-transfusion-dependent β-thalassemia (NTDT). * Pulmonary artery pressure (PAP) \> 35 mmHg estimated by Doppler echocardiography at screening. * Able and willing to provide written informed consent. * On a stable standard-of-care regimen (e.g., chelation and/or hydroxyurea) per treating physician judgment. Exclusion Criteria: * Age \<18 years. * Refusal or inability to provide informed consent. * Hepatic dysfunction: ALT \>3× upper limit of normal. * Renal dysfunction: serum creatinine \>2× upper limit of normal. * Known hypersensitivity to L-glutamine. * Pregnancy or breastfeeding. * Use of amino-acid/protein supplements within the past 3 months. * History of other cardiac diseases associated with pulmonary hypertension (per investigator assessment).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-transfusion dependent thalassemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

beta-thalassemia intermedia pulmonary hypertension thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-transfusion dependent thalassemia Pulmonary artery pressure Thalassemia

Contacts and locations

Locations

  • Bu'Ali Sina Hospital

    Sari, Mazandaran, 4815738477, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.